Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989495 | 0.81 | MEN1 (0.40) | MAPTTDP1RAB9ANPC1ALDH1A1 | |
| SCHEMBL1304147 | 0.79 | PDE10A (0.42) | MAPTCA1CA2TDP1RAB9A | |
| SCHEMBL12115830 | 0.78 | KDM4E (0.42) | TDP1RAB9ANPC1KDM4EPOLB | |
| SCHEMBL2944680 | 0.75 | ALDH1A1 (0.48) | MAPTCA1CA2TDP1ALDH1A1 | |
| SCHEMBL2949298 | 0.74 | ALDH1A1 (0.47) | MAPTCA1CA2TDP1ALDH1A1 | |
| SCHEMBL2950950 | 0.74 | ALDH1A1 (0.47) | MAPTCA1CA2TDP1ALDH1A1 | |
| SCHEMBL2949295 | 0.74 | ALDH1A1 (0.47) | MAPTCA1CA2TDP1ALDH1A1 | |
| SCHEMBL1304356 | 0.72 | MAPT (0.50) | MAPTCA1CA2TDP1RAB9A | |
| SCHEMBL29447590 | 0.71 | SPR (0.49) | MAPTTDP1RAB9ANPC1KDM4E | |
| SCHEMBL20400938 | 0.71 | SPR (0.49) | MAPTTDP1RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | MAPT 2527/4885CA1 3714/4885CA2 3562/4885 |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | MAPT 3514/4885CA1 3077/4885CA2 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.